GSK and Vir step up virus antibody treatment trials

virus
Credit: CC0 Public Domain

British pharmaceutical giant GlaxoSmithKline (GSK) and Californian laboratory Vir Biotechnology on Tuesday announced final stage testing of their potential coronavirus treatment.

The phase-three trials will evaluate the effectiveness of their "fully human anti-SARS-CoV-2 monoclonal antibody" VIR-7831 in the early treatment of patients at high risk of hospitalisation.

If successful, the companies believe it could increase the number of people who have tested positive for the virus being treated as outpatients.

GSK and Vir said in a joint statement the trials would take place in North America, South America and Europe after a "positive assessment of unblinded safety data".

They will involve some 1,300 people, half of whom will receive a placebo, and the other half VIR-7831, with preliminary results available as early as the end of this year.

Final results are likely in January next year.

VIR-7831 is described as having "the potential to neutralise the virus, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs".

GSK announced in April that it is investing £350 million in the US laboratory and would work together to fight COVID-19 and any future possible outbreaks.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2020 AFP

Citation: GSK and Vir step up virus antibody treatment trials (2020, October 6) retrieved 24 November 2020 from https://medicalxpress.com/news/2020-10-gsk-vir-virus-antibody-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments